Pfizer-BioNTech updated COVID shot shows strong immune response in high-risk groups
A total of 100 adults were enrolled in the trial
(Reuters): Pfizer (PFE.N), opens new tab and partner BioNTech (22UAy.DE), opens new tab said on Monday their updated COVID-19 vaccine showed an increased immune response in adults aged 65 and older as well as those aged 18 through 64 with at least one underlying risk condition.
Preliminary data from an ongoing late-stage trial showed at least a four-fold increase in levels of LP.8.1-neutralizing antibody after receiving the updated COVID-19 vaccine, the companies said.
A total of 100 adults were enrolled in the trial.
This study was conducted to provide additional information about immunological effects of the vaccine and is not intended to replace the post-marketing commitments requested by the US health regulator.
PM Shehbaz receives Trump’s invitation to join Gaza Peace Board
- 17 hours ago
Overseas jobs surge 5pc, remittances jump 9pc
- 17 hours ago
Italian PM calls threatened US tariffs over Greenland a ‘mistake’
- 17 hours ago
Six killed, 40 wounded in Karachi fire incident; 56 still missing
- 14 hours ago
World markets face fresh jolt as Trump vows tariffs on Europe over Greenland
- 16 hours ago
Junaid Safdar's walima ceremony held
- 14 hours ago
EU considers $108b in retaliatory tariffs on US over Trump's Greenland threat, FT reports
- 12 hours ago
Iran warns against any US strike as judiciary hints at unrest-linked executions
- 12 hours ago
The LG C5 and Apple’s M4 Mac Mini are both steeply discounted this weekend
- 7 hours ago
Dave Filoni takes charge of Star Wars as new president of Lucasfilm
- 7 hours ago
Police, CTD kill militant in D I Khan's IBO
- 17 hours ago
No No. 1 receiver? No problem! How Bills' offense can win without one
- 6 hours ago
